Engineered CAR‐T cells that target urokinase‐type plasminogen activator receptor (uPAR), which is expressed on fibrogenic, senescent hepatic myofibroblasts, also ameliorate liver fibrosis in vivo.[235] Interestingly, engineered bone marrow‐derived macrophages with a CAR to direct their phagocytic activity against uPAR‐expressing hepatic stellate cells or FAP‐expressing cardiac fibroblasts both demonstrated remarkable antifibrotic efficacy in mice.[236, 237] The therapeutic application of CAR in fibrotic diseases is currently under active development and investigation. This evidence concerns the gene PLAUR and Hepatic fibrosis.